Search results

5 results for rosuvastatin

Sorted by Relevance . Sort by Date

  1. Lipid-modifying drugs (KTT3)

    This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  2. Cardiovascular disease prevention

    Everything NICE has said on cardiovascular risk assessment and modifying blood lipids for preventing cardiovascular disease in adults

  3. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of cardiovascular problems including people with type 1 or type 2 diabetes, or chronic kidney disease. It describes the lifestyle changes people can make and how statins can be used to reduce their risk.

  4. Familial hypercholesterolaemia

    Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart